Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.41 |
| ▸ | ELOVL1 | Q9BW60 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11960323 | 0.98 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ANPC1TSHRRECQL | |
| SCHEMBL11960308 | 0.84 | HRH4 (0.53) | TSHRHRH4ALDH1A1CYP2C19HRH3 | |
| SCHEMBL10223327 | 0.83 | CYP2C19 (0.58) | SMN1; SMN2RAB9ANPC1LRRK2ELOVL1 | |
| SCHEMBL16903679 | 0.81 | LRRK2 (0.44) | LRRK2CYP2C19 | |
| SCHEMBL19548104 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2RAB9ANPC1TSHRRECQL | |
| SCHEMBL11960320 | 0.80 | LRRK2 (0.45) | LRRK2HRH4CYP2C19JAK2HRH3 | |
| SCHEMBL11960332 | 0.80 | LRRK2 (0.43) | TSHRLRRK2HRH4ALDH1A1CYP2C19 | |
| SCHEMBL25653338 | 0.78 | LRRK2 (0.47) | LRRK2HRH4ALDH1A1HRH3 | |
| SCHEMBL11960312 | 0.77 | LRRK2 (0.48) | SMN1; SMN2TSHRLRRK2CYP2C19JAK2 | |
| SCHEMBL25653356 | 0.77 | LRRK2 (0.49) | LRRK2HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | SMN1; SMN2 2617/4885RAB9A 1965/4885NPC1 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.